Gil Roth07.14.11
James Hoyes has been appointed president of EMD Serono, a U.S. affiliate of Merck KGaA. Mr. Hoyes will be responsible for driving the strategic direction of the U.S. commercial organization as well as managing the day-to-day business. Mr. Hoyes will also serve as a member of the executive management board for Merck Serono, the global pharmaceuticals division of Merck KGaA.
“Jim’s experience, leadership and vision will add significant value to our US operations,” said Dr. Stefan Oschmann, president of Merck Serono. “He has a strong knowledge of the industry and expertise across a variety of commercial functions, including sales, marketing, communications, managed markets, and collaborations. We are confident that Jim will enhance the reputation of EMD Serono as a leader in biopharmaceuticals in the U.S.”
Mr. Hoyes previously served as chief commercial officer for EMD Serono, responsible for business operations in the company’s key therapeutic areas of neurodegenerative diseases, rheumatology, fertility and metabolic endocrinology, as well as managed care, business intelligence, health outcomes, specialty pharmacy and commercial operations.
He joined EMD Serono in February 2004 as vice president of marketing in neurology, and has led the neurology franchise, managing the operations of sales, marketing, communications, call center operations, and medical affairs.
Prior to joining EMD Serono, Mr. Hoyes gained experience in a variety of commercial roles of increasing responsibilities at Elan, Sanofi and Sterling Drug. Mr. Hoyes also has extensive experience working in a partnership environment (such as co-promotion and joint venture agreements) with other biopharmaceutical companies such as Pfizer, BMS, UCB and Wyeth.
“Jim’s experience, leadership and vision will add significant value to our US operations,” said Dr. Stefan Oschmann, president of Merck Serono. “He has a strong knowledge of the industry and expertise across a variety of commercial functions, including sales, marketing, communications, managed markets, and collaborations. We are confident that Jim will enhance the reputation of EMD Serono as a leader in biopharmaceuticals in the U.S.”
Mr. Hoyes previously served as chief commercial officer for EMD Serono, responsible for business operations in the company’s key therapeutic areas of neurodegenerative diseases, rheumatology, fertility and metabolic endocrinology, as well as managed care, business intelligence, health outcomes, specialty pharmacy and commercial operations.
He joined EMD Serono in February 2004 as vice president of marketing in neurology, and has led the neurology franchise, managing the operations of sales, marketing, communications, call center operations, and medical affairs.
Prior to joining EMD Serono, Mr. Hoyes gained experience in a variety of commercial roles of increasing responsibilities at Elan, Sanofi and Sterling Drug. Mr. Hoyes also has extensive experience working in a partnership environment (such as co-promotion and joint venture agreements) with other biopharmaceutical companies such as Pfizer, BMS, UCB and Wyeth.